Quarterly EPS Estimate For Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Cited At $1.76


The average EPS estimate for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for the three months ending 2016-12-31 is given as $1.76.

You find that 7 days ago, the average EPS estimate on the stock was $1.76, while for the 30 days ago the average EPS estimate stood at $1.76.

If you look back further, you see that the average EPS estimate for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) 60 days ago was given as 1.76, while EPS estimate 90 days ago was quoted at $1.76.

The change in the stock’s EPS estimate over the last 7 days works out to 0%.

EPS estimate revisions

Over the last 7 days, EPS estimates for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have been revised up 0 times. In the same period, the EPS estimate has been revised down 0 times.

In the last 30 days, the stock has had its EPS estimate revised up 0 and it has been revised up 0 times over the last 60 days.

Up revisions in the last 90 days are 0 and up revisions in the last 120 days are 0.

But for the last 18 days, the company has seen its EPS revised up 0 times, offset by 2 down revisions in the same period.

The down revisions of EPS in last 30, 60, 90 and 120 days were 2, 2, 2 and 2.

What About EPS Surprises

Analysts predicted EPS of $1.76 for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for the period ended 2. But the company ended up posting actual EPS of $1.8 on 2016-08-09. The EPS estimate cited was worked out based on 3 estimates that analysts had issued on the stock.

Therefore, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted EPS surprise of $0.09 per share in dollar terms, which works out to 5.26%. The standard deviation of the actual EPS reported by the company and the average EPS estimate immediately before the earnings were released works out to $0.3.

Quarterly Sales Estimates

For the fiscal year 2016, the mean and median annual sales estimates for the company are given as $406.535 and $407.65. The estimates are based on the projections of 4 analysts.

So far, the highest annual sales estimate for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stands at$418.42. That compares with the lowest annual sales estimate of $392.42. Calculating the standard deviation of the extreme annual sales estimates leads you to 10.696%.

Annual sales estimate adjustments

In the last 7 days, 4 analysts have raised their annual sales estimates for the company. But over the same period, 4 analysts have trimmed their annual sales estimates.

With that, you find that the percentage change in mean annual sales estimate in the last 7 days works out to 0%.

Over the last one month, though, 4 analysts moved to raise their sales estimates for Jazz Pharmaceuticals plc (NASDAQ:JAZZ). That compares with 4 analysts who cut their sales estimate for the company in the same period. That leads you to -2.579% as the mean sales estimate change over the last one month.

If you look back further, you see that over the last three months, 4 analysts have moved raise their sales estimates Jazz Pharmaceuticals plc (NASDAQ:JAZZ). That offset by 4 analysts who in the same period lowered their sales estimates for the stock. That works out to percentage change in mean sales estimate of -3.327% over a period of three months.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 12 times, 1 visits today)